Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study - The Lancet Oncology

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial - The Lancet Oncology

Efficacy and Safety of Immune Checkpoint Inhibitors for Advanced Malignant Melanoma: A Meta-Analysis on Monotherapy Vs Combination Therapy

Nivolumab in Combination With Ipilimumab in BRAF V600 Wild-Type Unresectable or Metastatic Melanoma - The ASCO Post

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

Management of metastatic cutaneous melanoma: updates in clinical practice - Gustavo Schvartsman, Patricia Taranto, Isabella C. Glitza, Sanjiv S. Agarwala, Michael B. Atkins, Antonio C. Buzaid, 2019

Ipilimumab Plus Nivolumab Improves Survival in Melanoma With Brain Metastases - Cancer Therapy Advisor

OPDIVO® (nivolumab) + YERVOY® (ipilimumab) Efficacy in Metastatic Melanoma

Full article: Efficacy and safety of the combined use of ipilimumab and nivolumab for melanoma patients with brain metastases: a systematic review and meta-analysis

Cureus, Aggressive Stereotactic Radiosurgery Coupled With Immune and Targeted Therapy for Recurrent Melanoma Brain Metastases: A Case Report and Literature Review